| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
3,6-Dihydroxyflavone targets multiple pathways involved in cancer cell survival and proliferation. It activates the caspase cascade and cleaves PARP, leading to apoptosis. It suppresses the epithelial-mesenchymal transition in breast cancer cells by inhibiting the Notch signaling pathway. It increases intracellular oxidative stress and lipid peroxidation. It also exhibits antibacterial activity against Gram-positive bacteria through inhibition of β-ketoacyl acyl carrier protein synthase III (KAS III).
|
|---|---|
| ln Vitro |
In vitro, 3,6-Dihydroxyflavone is an anti-cancer agent that induces apoptosis in leukemia HL-60 cells via reactive oxygen species-mediated p38 MAPK/JNK pathway. It dose- and time-dependently decreases cell viability and induces apoptosis by activating the caspase cascade and cleaving PARP. It suppresses EMT in breast cancer cells by inhibiting the Notch signaling pathway. It exhibits antibacterial activity against Gram-positive bacteria.
|
| ln Vivo |
In vivo, 3,6-Dihydroxyflavone has robust in vivo chemopreventive data from multiple animal models. It has been studied for various effects, including antioxidant, anti-inflammatory, and neuroprotective properties. It has shown promise in preclinical studies as a natural antioxidant and modulator of inflammatory responses.
|
| Enzyme Assay |
3,6-Dihydroxyflavone's enzyme inhibition and receptor binding activities have been characterized in various assays. It inhibits bacterial KAS I and KAS III. It activates the caspase cascade and cleaves PARP. It inhibits the Notch signaling pathway. Binding and activity assays are performed using purified enzymes or cell-based systems.
|
| Cell Assay |
In vitro cell experiments with 3,6-Dihydroxyflavone use various cancer cell lines, including HL-60 leukemia cells and breast cancer cells. Cells are treated with the compound at various concentrations and time points. Cell viability, apoptosis markers, caspase activation, PARP cleavage, and Notch signaling are assessed.
|
| Animal Protocol |
In vivo animal studies with 3,6-Dihydroxyflavone have been conducted using multiple animal models for chemoprevention studies. The compound has been studied for its antioxidant, anti-inflammatory, and neuroprotective properties. Detailed protocols regarding dosage and treatment duration are available in the literature.
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Known human metabolites of 3,6-dihydroxyfavorone include (2S,3S,4S,5R)-3,4,5-trihydroxy-6-(6-hydroxy-4-oxo-2-phenylchromene-3-yl)oxaoxane-2-carboxylic acid. Pharmacokinetic data for 3,6-Dihydroxyflavone are limited in the available literature. As a flavonoid with a molecular weight of 254.24 g/mol, the compound may have moderate oral bioavailability. Further pharmacokinetic studies are needed. |
| Toxicity/Toxicokinetics |
3,6-Dihydroxyflavone is considered safe for research use at typical concentrations. As a natural product, it is generally considered to have a favorable safety profile. As a research compound, it is intended for laboratory use only and not for human consumption.
|
| References | |
| Additional Infomation |
3,6-Dihydroxyflavone has a molecular formula of C₁₅H₁₀O₄ and a molecular weight of 254.24 g/mol. It is a natural flavone with anti-cancer activity. It induces apoptosis via caspase cascade and PARP cleavage, suppresses EMT in breast cancer cells by inhibiting Notch signaling, and exhibits antibacterial activity against Gram-positive bacteria.
|
| Molecular Formula |
C15H10O4
|
|---|---|
| Molecular Weight |
254.2375
|
| Exact Mass |
254.058
|
| CAS # |
108238-41-1
|
| PubChem CID |
688659
|
| Appearance |
Light yellow to light brown solid powder
|
| Density |
1.472g/cm3
|
| Boiling Point |
477.1ºC at 760 mmHg
|
| Melting Point |
231-234ºC
|
| Flash Point |
186.2ºC
|
| Vapour Pressure |
6.55E-10mmHg at 25°C
|
| Index of Refraction |
1.712
|
| LogP |
2.871
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
19
|
| Complexity |
395
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
XHLOLFKZCUCROE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H10O4/c16-10-6-7-12-11(8-10)13(17)14(18)15(19-12)9-4-2-1-3-5-9/h1-8,16,18H
|
| Chemical Name |
3,6-dihydroxy-2-phenylchromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~66.67 mg/mL (~262.23 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.83 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9333 mL | 19.6665 mL | 39.3329 mL | |
| 5 mM | 0.7867 mL | 3.9333 mL | 7.8666 mL | |
| 10 mM | 0.3933 mL | 1.9666 mL | 3.9333 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
